MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails

Sumudu Katugampola1, Jianchao Wang1, Roger W Howell2

  • 1Division of Radiation Research, Department of Radiology, New Jersey Medical School, Rutgers University, Newark, New Jersey.

Insights

Artificial intelligence (AI) tools in MIRDcell V4 optimize radiopharmaceutical cocktails to minimize radiation dose for cancer treatment. This AI approach enhances therapeutic efficacy by determining optimal drug combinations and activities for improved patient outcomes.

Area of Science:

  • Nuclear medicine
  • Computational biology
  • Oncology

Background:

  • Radiopharmaceutical cocktails are crucial for cancer therapy due to non-uniform cell uptake.
  • Optimization strategies are needed to improve the efficacy of multi-agent radiopharmaceutical treatments.
  • Previous in vivo implementations lacked convincing results due to the absence of optimization.

Purpose of the Study:

  • To develop and present artificial intelligence (AI) tools for optimizing radiopharmaceutical cocktails.
  • To minimize the total number of radioactive decays needed to achieve a specific tumor cell surviving fraction (SF).
  • To provide tools for optimizing treatments for both single cells and multicellular tumor clusters.

Main Methods:

  • AI tools were developed in MIRDcell V4 using a sequential least-squares programming algorithm.
  • The algorithm identifies optimal molar activities for each drug in a cocktail to minimize total decays for a target SF.
  • Tools were validated using model data, flow cytometry, and 3D spheroid models.

Main Results:

  • A 2-drug combination reduced 211At decays by 1.6-fold compared to a single agent for breast cancer cells.
  • In a hypothetical cluster, a 2-drug combination using 195mPt required 1.7-fold fewer decays than single agents.
  • Two 225Ac-labeled drugs reduced required disintegrations by half compared to the best single agent.

Conclusions:

  • MIRDcell AI tools effectively determine optimized drug combinations and molar activities for cancer therapy.
  • This AI-driven approach can predict the best drug combinations for maximum therapeutic effect with minimal radiation exposure.
  • The methodology holds potential for personalized cancer treatment by analyzing patient-specific cell samples.